NCT05998408View on ClinicalTrials.gov

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

June 3, 2030

Study Completion Date

June 3, 2032

Conditions
Severe Aplastic AnemiaSingle Lineage Cytopenias, T-LGLHypoplastic MDS
Interventions
DRUG

Ruxolitinib

Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH